Previous 10 | Next 10 |
home / stock / sphry / sphry news
Molnupiravir results are striking for very early treatment, but this doesn't compare with vaccination; the time window for effect is short and the trial was mostly with unvaccinated people. Merck has a Phase 3 trial testing if molnupiravir can prevent infection of a person exposed to ...
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments PR Newswire MELBOURNE, Australia , Sept. 15, 2021 /PRNewswire/ -- DEP ® cabazitaxel is a proprietary nanopar...
The delta variant of SARS-CoV-2 is changing the rules of engagement because it is highly infectious and it gets passed on rapidly. Scientific discoveries help explain why antivirals are ineffective and why nasal treatment looks powerful. Once the virus gets started in a sensitive indi...
Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model PR Newswire MELBOURNE, Australia , Aug. 23, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma has announced the publication of new data demonstrati...
MELBOURNE, Australia, June 24, 2021 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, OTCQX: SPHRY), based in Melbourne, Australia, today announced that Dr. Jackie Fairley, Chief Executive Officer, will present a pre-recorded presentation at LifeSciencesInvestorForum.com on June 24 th ...
NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and ...
Merck/Ridgeback Bio partnership on tablet form of antiviral molnuparivir attracts US Government interest for early-stage COVID treatment. Starpharma’s Viraleze for prevention and early-stage COVID treatment as a nasal spray gets traction in Europe and India. Monoclonal anti...
Starpharma rises on a partnership with Merck on DEP-Antibody Drug Conjugates. AstraZeneca AZD0466 (with Starpharma DEP technology) Phase 1 trial goes global. Viraleze, registered in Europe and positioned as a COVID preventative/early treatment, stable at room temperature and compa...
Pfizer sees $15 billion revenue from the Pfizer/BioNTech COVID vaccine in 2021 and it could completely change Pfizer’s revenue and earnings trajectory. Think about what this will do for BioNTech. The above revenues are for the “pandemic phase.” Pfizer/BioNTech may...
Starpharma signs DEP® ADC Research Agreement with MSD PR Newswire MELBOURNE, Australia , Feb. 11, 2021 /PRNewswire/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD , the tradename of Merck &am...
News, Short Squeeze, Breakout and More Instantly...
Starpharma Hldgs S/Adr Company Name:
SPHRY Stock Symbol:
OTCMKTS Market:
Uni Charm Corporation ADR (UNICY) is expected to report for Q2 2023 Clarus Therapeutics Hldgs (CRXTQ) is expected to report for quarter end 2023-06-30 Bed Bath & Beyond Inc. (BBBYQ) is expected to report for Q2 2024 CalAmp Corp. (CAMP) is expected to report $-0.04 for Q2 2024 ...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...
Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...